Bleomycin/cis-platin as neoadjuvant chemotherapy before radical radiotherapy in localized, inoperable carcinoma of the esophagus. A prospective randomized multicentre study: the second Scandinavian trial in esophageal cancer

Radiother Oncol. 1992 Jun;24(2):114-6. doi: 10.1016/0167-8140(92)90288-6.

Abstract

Survival and swallowing function were studied in a randomized trial of 97 patients with inoperable, localized esophageal carcinoma. Radical radiotherapy was given to 51 patients, while 46 patients had two courses of bleomycin/cisplatin before radiotherapy. The survival was 29% after one year, and 6% after 3 years in the radiotherapy group. The survival in the combined treatment group was 18 and 0%, respectively; p = 0.1895. The number of patients who could swallow any food increased from 6% before treatment to 38% after 3 months in the radiotherapy group, and from 0% to 23% in the combined group. No benefit was found by combining bleomycin/cisplatin with radiotherapy.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Bleomycin / administration & dosage
  • Bleomycin / therapeutic use*
  • Chemotherapy, Adjuvant
  • Cisplatin / administration & dosage
  • Cisplatin / therapeutic use*
  • Combined Modality Therapy
  • Deglutition / drug effects
  • Deglutition / physiology
  • Deglutition / radiation effects
  • Esophageal Neoplasms / drug therapy
  • Esophageal Neoplasms / epidemiology
  • Esophageal Neoplasms / radiotherapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Scandinavian and Nordic Countries / epidemiology
  • Survival Rate

Substances

  • Bleomycin
  • Cisplatin